© 2024 Intra-Cellular Therapies Inc. All rights reserved.
Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer
Mr. Neumann joins ITCI from
Prior to
“Mark is a proven leader with broad experience developing and implementing commercial strategies for early and late-stage assets within neuroscience and cardiovascular therapeutic fields. We believe his expertise further strengthens and complements our growing organization as we prepare for the commercialization of lumateperone and further advance our pipeline,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
"I am very excited to join the leadership team at Intra-Cellular Therapies and look forward to leading the commercial organization as we advance the launch preparations for lumateperone as well as developing commercial strategies for the Company’s pipeline,” said Mr. Neumann.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with Alzheimer's disease, depression, and other neuropsychiatric and neurological disorders. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of Parkinson's disease and heart failure.
INVESTORS:
Vice President, Corporate Communications and Investor Relations
646-440-9333
agray@burnsmc.com
212-213-0006
MEDIA INQUIRIES:
Corporate Media Relations, WCG World
pryan@wcgworld.com
Source: Intra-Cellular Therapies Inc.